SEC 13F Intelligence

Managers / Q2 2021 · view latest →

FRAZIER MANAGEMENT LLC

CIK 0001032165 · 601 UNION ST, SUITE 2110, SEATTLE, WA, 98101 · 2066217200

Reported Value
$1.1B
Q2 2021
Positions
34
Filings on Record
16
2019–present window
Filed
Aug 11, 2021
original filing

Summary

Frazier Management LLC reported $1.1B in U.S.-listed holdings across 34 positions for Q2 2021.

The portfolio is heavily concentrated: ARQT alone accounts for 21.2% of reported value.

Compared with Q1 2021, the fund opened 2 new positions and exited 3.

Portfolio Metrics

Turnover
+6.8%
vs prior filed quarter
Top-10 Concentration
+78.0%
share of reported value
Largest Position
+21.2%
Arcutis Biotherapeutics
New / Exited
2 / 3
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $388MQ4 ’18Q1 ’19: $415MQ2 ’19: $390MQ2 ’19Q3 ’19: $320MQ4 ’19: $596MQ4 ’19Q1 ’20: $882MQ2 ’20: $1.1BQ2 ’20Q3 ’20: $1.1BQ4 ’20: $1.3BQ4 ’20Q1 ’21: $1.2BQ2 ’21: $1.1BQ2 ’21Q3 ’21: $1.2BQ4 ’21: $1.3BQ4 ’21Q2 ’22: $1MQ3 ’22: $0Q3 ’22filingsflow.com

Portfolio Composition

By security type
Common Stock: 81.4%Other: 17.2%ADR: 1.4%
  • Common Stock · 81.4% · $883M
  • Other · 17.2% · $186M
  • ADR · 1.4% · $15M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
CHINOOK THERAPEUTICS INCNEW+1.10M1.10M+$16M$16M
AUTLAUTOLUS THERAPEUTICS PLCNEW+2.28M2.28M+$15M$15M
ADVERUM BIOTECHNOLOGIES INCSOLD OUT−1.44M0−$14M$0
CRDFCARDIFF ONCOLOGY INCSOLD OUT−293.5K0−$3M$0
ITERUM THERAPEUTICS PLCSOLD OUT−1.54M0−$2M$0
IOVAIOVANCE BIOTHERAPEUTICS INCADDED+825.0K2.14M+$14M$56M
IMVTIMMUNOVANT INCTRIMMED−254.0K254.0K−$5M$3M
ACRSACLARIS THERAPEUTICS INCTRIMMED−325.3K370.7K−$11M$7M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2021

34 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1ARQTARCUTIS BIOTHERAPEUTICS INChistory →COM21.23%$230M8.43M
2PHATPHATHOM PHARMACEUTICALS INChistory →COM18.19%$197M5.83M
3PASSAGE BIO INCCOM6.12%$66M5.01M
4MIRMMIRUM PHARMACEUTICALS INChistory →COM5.69%$62M3.57M
5TRANSLATE BIO INCCOM5.29%$57M2.08M
6IOVAIOVANCE BIOTHERAPEUTICS INChistory →COM5.13%$56M2.14M
7KRYSKRYSTAL BIOTECH INChistory →COM4.94%$54M787.9K
8PCVXVAXCYTE INChistory →COM4.79%$52M2.31M
9TARSTARSUS PHARMACEUTICALS INChistory →COM3.79%$41M1.42M
10TREURTRILLIUM THERAPEUTICS INChistory →COM NEW2.79%$30M3.12M
11ANABANAPTYSBIO INChistory →COM2.15%$23M899.7K
12ALPINE IMMUNE SCIENCES INCCOM2.13%$23M2.57M
13SNDXSYNDAX PHARMACEUTICALS INChistory →COM1.88%$20M1.19M
14SUTRO BIOPHARMA INCCOM1.72%$19M1.00M
15IVERIC BIO INCCOM1.48%$16M2.54M
16CHINOOK THERAPEUTICS INCCOM1.43%$16M1.10M
17AUTLAUTOLUS THERAPEUTICS PLChistory →SPON ADS1.40%$15M2.28M
18FRAZIER LIFESCIENCES ACQU COUNIT 12/09/20251.39%$15M1.50M
19RGNXREGENXBIO INChistory →COM1.26%$14M352.0K
20MOLECULAR TEMPLATES INCCOM0.99%$11M1.37M
21GRITSTONE BIO INCCOM0.87%$9M1.03M
22ESSA PHARMA INCCOM NEW0.83%$9M316.6K
23ACRSACLARIS THERAPEUTICS INCCOM0.60%$7M370.7K
24EPIZYME INCCOM0.57%$6M739.4K
25APTINYX INCCOM0.49%$5M1.88M
26SRRKSCHOLAR ROCK HLDG CORPCOM0.42%$5M156.0K
27FREELINE THERAPEUTICS HLDGSSPONSORED ADS0.41%$4M550.0K
28ALLENA PHARMACEUTICALSCOM0.40%$4M3.33M
29BLUBELLUS HEALTH INC NEWCOM NEW0.37%$4M1.30M
30SIERRA ONCOLOGY INCCOM NEW0.36%$4M202.8K
31AVADEL PHARMACEUTICALS PLCSPONSORED ADR0.36%$4M578.1K
32IMVTIMMUNOVANT INCCOM0.25%$3M254.0K
33GRTXGALERA THERAPEUTICS INCCOM0.22%$2M241.0K
34NABRIVA THERAPEUTICS PLCSHS0.05%$575,000425.6K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2022$01Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1M1Aug 10, 202213F-HRchanges · EDGAR ↗
Q1 2022Under review2May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$1.3B43Feb 8, 202213F-HRchanges · EDGAR ↗
Q3 2021$1.2B41Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$1.1B34Aug 11, 202113F-HRchanges · EDGAR ↗
Q1 2021$1.2B35May 12, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.3B35Feb 11, 202113F-HRchanges · EDGAR ↗
Q3 2020$1.1B31Nov 12, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.1B26Aug 4, 202013F-HRchanges · EDGAR ↗
Q1 2020$882M25May 13, 202013F-HRchanges · EDGAR ↗
Q4 2019$596M20Feb 13, 202013F-HRchanges · EDGAR ↗
Q3 2019$320M19Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$390M18Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$415M17May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$388M17Feb 11, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.